Body composition changes in protease inhibitor‐naive HIV‐infected patients treated with two nucleoside reverse transcriptase inhibitors

Tsekes, Georgios; Chrysos, George; Douskas, G.; Paraskeva, Dimitra; Mangafas, Nikos; Giannakopoulos, D; Papanikolaou, Maria; Georgiou, Evangelos; Lazanas, M

doi:10.1046/j.1468-1293.2002.00105.x

Cited by 32 publications

(21 citation statements)

References 19 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Previous reports suggest that boosted PI is associated with lower bone mineral content and TB BMD [6]. Others have found adverse bone effects associated with regimens containing lamivudine and zidovudine [25, 26]. Indinavir is known to increase osteoclast activity [27].…”

Section: Discussionmentioning

confidence: 99%

Bone mineral density in children and adolescents with perinatal HIV infection

DiMeglio

Wang

Siberry

et al. 2013

Aids

View full text Add to dashboard Cite

Objective To estimate prevalence of low bone mineral density (BMD) in perinatally HIV infected (HIV+) and HIV-exposed but uninfected (HEU) children, and to determine predictors of BMD in HIV+. Design Cross-sectional analysis within a 15-site United States and Puerto Rico cohort study. Methods Total body (TB) and lumbar spine (LS) BMD were measured using dual energy-xray absorptiometry. BMD Z-scores accounted for bone age and sex. Multiple linear regression was used to evaluate differences in Z-scores by HIV status and for predictors of BMD in HIV+. Results 350 HIV+ and 160 HEU were enrolled. Mean age was 12.6 and 10.7 years for HIV+ and HEU, respectively. Most (87%) HIV+ were receiving highly active antiretroviral therapy (HAART). More HIV+ than HEU had TB and LS Z-scores < -2.0 (TB: 7% vs. 1%, p=0.008; LS: 4% vs. 1%, p=0.08). Average differences in Z-scores between HIV+ and HEU were attenuated after height and/or weight adjustment. Among HIV+, TB Z-scores were lower in those with higher CD4% and in those who ever used boosted protease inhibitors or lamivudine. LS Z-scores were lower with higher peak viral load and CD4%, more years on HAART, and ever use of indinavir. Conclusions Rates of low BMD in HIV+ children were greater than expected based on normal population distributions. These differences were partially explained by delays in growth. Since most HIV+ children in this study had not entered their pubertal growth spurt, prepubertal factors associated with BMD, magnified or carried forward, may result in sub-optimal peak BMD in adulthood.

show abstract

Section: Discussionmentioning

confidence: 99%

Bone mineral density in children and adolescents with perinatal HIV infection

DiMeglio

Wang

Siberry

et al. 2013

Aids

View full text Add to dashboard Cite

show abstract

“…A low nadir CD4 cell count has been shown to be an independent risk factor for both reduced BMD and increased fracture incidence after adjustment for BMI (34). Time from date of diagnosis and prolonged exposure to unsuppressed HIV was also found to be an independent risk factor for loss of BMD in three studies (33).…”

Section: Does Hiv Cause Low Bone Mineral Density?mentioning

confidence: 99%

Bone Metabolism and HIV Infection

Coaccioli¹

2011

HIV Infection in the Era of Highly Active Antiretroviral Treatment and Some of Its Associated Complications

View full text Add to dashboard Cite

“…Similarly, Carr et al reported that 3% of 44 HIV-infected patients receiving NRTIs developed osteoporosis and 22% developed osteopenia [39], while in a study examining HIV-1 infected men Mallon et al determined a reduction in BMD beginning at 48 weeks post initiation of treatment [40]. Tsekes et al determined BMD and whole body fat by dual-energy X ray absorbance (DEXA) of HIV-infected patients receiving Zidovudine (AZT) and other NRTIs and found significant decreases in both body fat and BMD [41].…”

Section: Hiv-1 Associated Bone Abnormalitiesmentioning

confidence: 99%

Progenitor Cell Types in HIV-1 Infection: Bioactivity and Emerging Targets for Treatment

Cotter¹,

Doran²,

Powderly

2009

CHR

View full text Add to dashboard Cite

HIV-1 exerts its most profound effects through destruction of the host's immune responses specifically through targeting of the T-lymphocyte populations. In addition to its primary immune target, HIV-1 also targets cells of the nervous, skeletal and vascular system. There is emerging evidence to suggest that HIV-1 may, in part at least, affect these diverse tissues by impairing the homeostatic production of terminally differentiated cells from stem and progenitor cell populations. The interaction between HIV-1 and stem cell populations may serve to underpin the diverse non-immunological effects of HIV-1. This review deals with the effect of HIV-1 infection on a number of progenitor cell types, with emphasis on delineating mechanisms of HIV's destructive effect on the body. Modification of these effects may represent novel avenues for exploration in our search for clinical interventions.

show abstract

Body composition changes in protease inhibitor‐naive HIV‐infected patients treated with two nucleoside reverse transcriptase inhibitors

Abstract: Dual NRTI therapy contributes to fat loss and reduction of bone mineral content in otherwise healthy, clinically stable, PI-naive HIV-infected adults. Compared with patients on ZDV + ddI, patients on ZDV + 3TC had a more prominent fat loss in all body regions.

Cited by 32 publications

References 19 publications

Bone mineral density in children and adolescents with perinatal HIV infection

Bone mineral density in children and adolescents with perinatal HIV infection

Bone Metabolism and HIV Infection

Progenitor Cell Types in HIV-1 Infection: Bioactivity and Emerging Targets for Treatment

Contact Info

Product

Resources

About